Precision BioSciences (DTIL) shares soared 11.1% in the last trading session to close at $6.5. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 25.3% gain over the past four weeks.The sudden rise in the stock price can be attributed to the positive investor mindset regarding the potential of Precision BioSciences’ clinical-stage pipeline. The company is currently developing its lead, fully owned in vivo gene editing therapy, PBGEN ...